Gene therapy’s evidence problem–lessons from recent FDA decisions
BioSpace
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than early-stage clinical trials of candidates from REGENXBIO, Excision BioTherapeutics a
pharminent
May 4, 2026 (Last updated: May 4, 2026)
BioSpace
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than early-stage clinical trials of candidates from REGENXBIO, Excision BioTherapeutics a
